Jpmorgan Chase & CO Bicycle Therapeutics PLC Call Options Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding BCYC
# of Institutions
113Shares Held
41.1MCall Options Held
3.4KPut Options Held
12.4K-
Baker Bros. Advisors LP New York, NY9.4MShares$221 Million2.53% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.49MShares$81.9 Million2.32% of portfolio
-
Ra Capital Management, L.P. Boston, MA2.25MShares$52.9 Million0.69% of portfolio
-
Fcpm Iii Services B.V. Naarden, P72.12MShares$49.8 Million6.34% of portfolio
-
Armistice Capital, LLC New York, NY1.97MShares$46.3 Million0.52% of portfolio
About BICYCLE THERAPEUTICS plc
- Ticker BCYC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,676,100
- Market Cap $696M
- Description
- Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...